Dopamine 2 agonists for the management of type 2 diabetes: a systematic review and meta-analysis

被引:0
作者
Beyene Dereje
Aschalew Nardos
机构
[1] Dire Dawa University,Department of Pharmacology, School of Medicine, College of Medicine and Health Sciences
[2] Hawassa University,Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences
来源
Journal of Diabetes & Metabolic Disorders | 2023年 / 22卷
关键词
Bromocriptine; Cabergoline; FBS; HbA1c; Dopamine 2 agonist; Meta-analysis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:931 / 943
页数:12
相关论文
共 216 条
[1]  
Care D(2022)Introduction: Standards of medical care in diabetes — 2022 Diabetes Care 45 2021-2
[2]  
Suppl SS(2022)Gut microbiota and complications of type-2 diabetes Nutrients 49 2022-15
[3]  
Iatcu CO(2017)Complications resulting from uncontrolled diabetes MLO Med Lab Obs 7 1-56
[4]  
Steen A(2021)International Diabetes Federation Diabetes Res Clin Pract 17 437-23
[5]  
Covasa M(2018)Current trends in pharmacological treatment of type II diabetes mellitus Int J Pharmacol Res Rev 131 1-5
[6]  
Molinaro R(2021)Herbal medicines for diabetes management and its secondary complications Curr Diabetes Rev 10 60-8
[7]  
Dauscher C(2020)Type II diabetes mellitus: a review on recent drug based therapeutics Biomed Pharmacother 41 197-80
[8]  
Ingle PV(2016)A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters Prim Care Diabetes 109 74-94
[9]  
Yin SB(2009)Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes Indian J Pharmacol 34 789-10
[10]  
Ying BJ(2016)Dopaminergic drugs in type 2 diabetes and glucose homeostasis Pharmacol Res 68 1-404